Nakao M
Pharmaceutical Research Laboratories III, Takeda Chemical Industries, Ltd., Osaka, Japan.
J Clin Gastroenterol. 1995;20 Suppl 1:S32-7. doi: 10.1097/00004836-199506001-00008.
The activities of various types of anti-ulcer agents against Helicobacter pylori (Hp) strains were determined using an agar dilution method. Among the compounds tested, proton pump inhibitors were found to exhibit significant activity against this organism. The activity of lansoprazole was four times more potent than that of omeprazole and bismuth subsalicylate, with MICs ranging from 1.56 to 25 micrograms/ml. Exposure of Hp to lansoprazole led to extensive loss of viability and suppression of virulence factors such as motility, adhesiveness to epithelial cells, and urease activity. Lansoprazole produced aberrant bacterial morphology characterized by elongation and constriction of the cells and collapse of cell surface structures. The combination of lansoprazole with antimicrobial agents such as penicillins, cephalosporins, macrolides, tetracyclines, aminoglycosides, quinolones, and metronidazole produced an additive or synergistic growth inhibition of Hp.
采用琼脂稀释法测定了各类抗溃疡药物对幽门螺杆菌(Hp)菌株的活性。在所测试的化合物中,发现质子泵抑制剂对该菌具有显著活性。兰索拉唑的活性比奥美拉唑和次水杨酸铋强四倍,其最低抑菌浓度(MIC)范围为1.56至25微克/毫升。Hp暴露于兰索拉唑后导致活力大量丧失,并抑制了诸如运动性、对上皮细胞的粘附性和脲酶活性等毒力因子。兰索拉唑导致细菌形态异常,其特征为细胞伸长和收缩以及细胞表面结构塌陷。兰索拉唑与抗菌剂如青霉素、头孢菌素、大环内酯类、四环素类、氨基糖苷类、喹诺酮类和甲硝唑联合使用,对Hp产生了相加或协同的生长抑制作用。